Calliditas Therapeutics IPO Presentation Deck
Primary Biliary Cholangitis
The disease
Primary Biliary Cholangitis (PBC) is a progressive and
chronic autoimmune disease of the liver¹
Early symptoms include fatigue, itchy skin and dry
eyes/mouth. Later stages - liver stiffness,
musculoskeletal pain, edema, jaundice and underactive
thyroid
Estimated prevalence
140,000
Annual U.S.
incidence
0.3-5.8 per
100,000
Standard of care
Ursodeoxycholic acid (UDCA) and obeticholic acid (Ocaliva) are the only FDA-approved medical treatments
for PBC²
No targeted anti-inflammatory therapy is approved in the U.S. or Europe
Previous trials indicates that corticosteroids may alleviate symptoms and improve biochemical and
histologic findings³
Sou 1) Linder et tepalogy, 2009 5/11291-30 EASL PC Cinical Practice Guidelines, Journal of Hepatology 2017, 62 545-172 2) met Gastroterology 2000 129-1633-163) CASE PBC Cinca Practice Guenes, Journal of Hepatology 2017, 67 145-1724) Compony estimate based on prevence
reported by Kim et al Gastroenterology 2000 1196 1631-6 and Nguyen et al, Best Pract Res Clin Gastroenterol 2010; 245.647-54 5) Nguyen et al, Best Pract Res Clin Gastroenterol 2010; 3415): 647-654
calliditas
June 2020
28View entire presentation